Dystonia Clinical Trial
Official title:
Placebo Controlled Study of the Therapeutic Effect of the Transcranial Electrical Polarization in Patients With Focal Hand Dystonia
Verified date | May 14, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the effect of transcranial electrical polarization (TEP), also
called direct current (DC) stimulation, on focal hand dystonia in people with writer's cramp.
In dystonia, muscle spasms cause uncontrolled twisting and repetitive movement or abnormal
postures. Focal dystonia involves just one part of the body, such as the hand, neck or face.
When people with focal hand dystonia make small and repeated movements with their hands,
there is extra activity in the part of the brain called the motor cortex. TEP is a method of
brain stimulation that slows down the activity of the nerve cells in the motor cortex. This
study may help researchers develop new ways to treat focal hand dystonia.
People 18 years of age and older with focal hand dystonia may be eligible for this study.
Participants have a neurological examination and are randomly assigned to one of two
treatment groups: TEP or placebo stimulation. The TEP group receives stimulation to the parts
of the brain used for hand movement, and the placebo group receives sham stimulation, which
does not affect any area of the brain. There are three TEP/placebo sessions over a period of
7 to 10 days. The first session may last up to 2-1/2 hours; the other two sessions last 1-2
hours.
For TEP, sponge electrodes are placed on the scalp and an electrical current is passed
through the scalp and skull to the outer part of brain. Before and after each session,
participants have a neurological examination, including an evaluation of the rate and
severity of their movement problems. For this assessment, participants do a writing test
while the electrical activity of their hand muscles is recorded using surface
electromyography (EMG). For EMG, small metal disks (electrodes) filled with a conductive gel
are taped to the skin over the muscles being tested.
Patients are followed in the clinic the day after the end of TEP treatment for evaluation of
their movement abilities and the effects of therapy, such as improvement of handwriting.
Status | Completed |
Enrollment | 12 |
Est. completion date | May 14, 2010 |
Est. primary completion date | May 14, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: - Subjects with focal hand dystonia 18 years old or older will be included. EXCLUSION CRITERIA: Exclusion criteria will include the standard exclusions for TEP as well as exclusions specific to this study. We will exclude subjects with: - Any significant medical or psychiatric illness (other than FHD). - Patients with a positive pregnancy test will be excluded because the effects of TEP on the fetus is unknown. A urine sample for pregnancy testing will be obtained prior to the TEP, and on the day of the first TEP session. - History of epilepsy. - Concurrent use of neuroleptic agents. - Any other licit or illicit drugs other that could lower the seizure threshold. - Metal implants. - Who have received botulinum toxin injection within 10 weeks of starting the protocol. - Secondary hand dystonia. - Mentally impaired patients having no capacity to provide their own consent will be excluded from the study because such patients may have difficulty performing the required test. - If participation in the study would, in the opinion of the investigators, cause undue risk or stress for reasons such as excessive fatigue, general frailty, or excessive apprehension. - Unable or unwilling to refrain from alcohol for 24 hours prior to study days. Patients may continue taking muscle relaxants, artane and other anticholinergic drugs, L-DOPA and dopamine agonists. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Agnew WF, McCreery DB. Considerations for safety in the use of extracranial stimulation for motor evoked potentials. Neurosurgery. 1987 Jan;20(1):143-7. — View Citation
Antal A, Nitsche MA, Paulus W. External modulation of visual perception in humans. Neuroreport. 2001 Nov 16;12(16):3553-5. — View Citation
Chen R, Wassermann EM, Caños M, Hallett M. Impaired inhibition in writer's cramp during voluntary muscle activation. Neurology. 1997 Oct;49(4):1054-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Fahn Dystonia Scale before and after real and placebo TEP course. | 1 week post-TEP |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01433757 -
Ampicillin for DYT-1 Dystonia Motor Symptoms
|
Phase 1 | |
Recruiting |
NCT00971854 -
Alteration of Deep Brain Stimulation Parameters for Dystonia
|
N/A | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00169338 -
Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia
|
Phase 2 | |
Completed |
NCT00004421 -
Deep Brain Stimulation in Treating Patients With Dystonia
|
Phase 2/Phase 3 | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Recruiting |
NCT02583074 -
Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia
|
N/A | |
Recruiting |
NCT06117020 -
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
|
Phase 1 | |
Completed |
NCT01432899 -
Studying Childhood-Onset Hemidystonia
|
||
Completed |
NCT04948684 -
Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
|
||
Completed |
NCT05106816 -
The Effects of Vibrotactile Stimulation in Patients With Movement Disorders
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
Active, not recruiting |
NCT00142259 -
Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia
|
Phase 4 | |
Recruiting |
NCT05663840 -
Effects of Exercise on Dystonia Pathophysiology
|
N/A | |
Not yet recruiting |
NCT06038097 -
Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia
|
N/A | |
Recruiting |
NCT04286308 -
Cortical-Basal Ganglia Speech Networks
|
N/A | |
Active, not recruiting |
NCT03582891 -
The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy
|
N/A | |
Completed |
NCT03318120 -
Exercise Training in Dystonia
|
N/A | |
Completed |
NCT04568681 -
Deep Brain Stimulation Effects in Dystonia
|